BRCA1 and ovarian cancer: In contrast to breast and ovarian cancers, BRCA1/2 germ-line alterations, although being presumably a cause of LC disease in mutation carriers, are not always accompanied by the loss of the remaining BRCA1/2 allele, so they are not necessarily associated with tumor sensitivity to PARP inhibitors [155].